NPD8716

NPD8716 directly binds to recombinant NTCP-His in a dose-dependent manner, as detected by SPR analysis^[1].
NPD8716 dose-dependently inhibits NTCP-mediated bile acid uptake in HepG2-hNTCP-C4 cells in vitro, with an IC₅₀ of 17.8 μM^[1].
NPD8716 (25-200 μM; 16 h coincubation with HBV, followed by 12 days of culture without compound) inhibits HBV infection in HepG2-hNTCP-C4 cells in a dose-dependent manner, with no cytotoxicity^[1].
NPD8716 (40 μM for the first 3 days, then switched to 20 μM until day 24 or day 36; or continuously administered at 60 μM until day 24) inhibits the spread of HBV in freshly isolated primary human hepatocytes when administered at the time of inoculation or 48 h post-inoculation^[1].
NPD8716 (200 μM; 6 days) does not inhibit HBV replication in Hep38.7-Tet cells, indicating that its anti-HBV activity does not target the viral replication process^[1].
NPD8716 (200 μM; 30 min) blocks HBV preS1-mediated adhesion to HepG2-hNTCP-C4 cells and interferes with the initial step of viral invasion^[1].
NPD8716 (200 μM) specifically inhibits NTCP-mediated viral entry, as it blocks HDV infection in HepG2-hNTCP-C4 cells but does not suppress HCV infection in Huh-7.5.1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.